Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells

Cancer Research

Volumn 68, Issue 1, 2008, Pages 257-265

  Evans, James W ^a   Chernikova, Sophia B ^a   Kachnic, Lisa A ^b   Banath, Judit P ^d   Sordet, Olivier ^e   Delahoussaye, Yvette M ^a   Treszezamsky, Alejandro ^c   Chon, Brian H ^c   Feng, Zhihui ^c   Gu, Yongchuan ^f   Wilson, William R ^f   Pommier, Yves ^e   Olive, Peggy L ^d   Powell, Simon N ^c   Brown, J Martin ^a,g  

^a STANFORD UNIVERSITY   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; DNA TOPOISOMERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE H2AX; RAD51 PROTEIN; TIRAPAZAMINE; XRCC3 PROTEIN; ANTINEOPLASTIC AGENT; DNA; DNA BINDING PROTEIN; ENDONUCLEASE; H2AFX PROTEIN, HUMAN; HISTONE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE S PHASE; COMPLEX FORMATION; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN PHOSPHORYLATION; SISTER CHROMATID; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETIC RECOMBINATION; GENETICS; HAMSTER; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRICETINAE; DNA; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HISTONES; HUMANS; MUTATION; PHOSPHORYLATION; RECOMBINATION, GENETIC; TRIAZINES;

EID: 39149094633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4497     Document Type: Article

References (51)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
2. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-202.
3. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multicenter study. Radiother Oncol 2005;77:18-24.
4. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
5. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol 2000;18:1351-9.
6. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42.
7. Baker MA, Zeman EM, Hirst VK, Brown JM. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res 1988;48:5947-52.
8. Zagorevskii D, Song M, Breneman C, et al. A mass spectrometry study of tirapazamine and its metabolites: insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. J Am Soc Mass Spectrom 2003;14:881-92.
9. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 2003;125:748-56.
10. Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 1992;52:4473-7.
11. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002;62:5248-53.
12. Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N. Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Nucleic Acids Res 2003;31:4373-84.
13. Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage. Mol Cancer Ther 2006;5:1405-14.
14. Adachi N, Suzuki H, Iiizumi S, Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 2003;278:35897-902.
15. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002;30:3848-56.
16. Hinz JM, Tebbs RS, Wilson PF, et al. Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res 2006;34:1358-68.
17. Banath JP, Wallace SS, Thompson J, Olive PL. Radiation-induced DNA base damage detected in individual aerobic and hypoxic cells with endonuclease III and formamidopyrimidine-glycosylase. Radiat Res 1999;151:550-8.
18. Zhitkovich A, Costa M. A simple, sensitive assay to detect DNA-protein cross-links in intact cells and in vivo. Carcinogenesis 1992;13:1485-9.
19. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55:2097-103.
20. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-91.
21. Wilson DM III, Thompson LH. Molecular mechanisms of sister-chromatid exchange. Mutat Res 2007;616:11-23.
22. Blunt T, Finnie NJ, Taccioli GE, et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 1995;80:813-23.
23. Kirchgessner CU, Patil CK, Evans JW, et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995;267:1178-83.
24. Gu Y, Jin S, Gao Y, Weaver DT, Alt FW. Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci U S A 1997;94:8076-81.
25. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000;275:26632-6.
26. Adair GM, Rolig RL, Moore-Faver D, Zabelshansky M, Wilson JH, Nairn RS. Role of ERCC1 in removal of long non-homologous tails during targeted homologous recombination. EMBO J 2000;19:5552-61.
27. Delahoussaye YM, Evans JE, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol 2001;62:1201-9.
28. Kotandeniya D, Ganley B, Gates KS. Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). Bioorg Med Chem Lett 2002;12:2325-9.
29. Jones GD, Weinfeld M. Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res 1996;56:1584-90.
30. Birincioglu M, Jaruga P, Chowdhury G, Rodriguez H, Dizdaroglu M, Gates KS. DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Am Chem Soc 2003;125:11607-15.
31. Wilstermann AM, Osheroff N. Base excision repair intermediates as topoisomerase II poisons. J Biol Chem 2001;276:46290-6.
32. Thompson LH, West MG. XRCC1 keeps DNA from getting stranded. Mutat Res 2000;459:1-18.
33. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50.
34. Hellauer K, Lesage G, Sdicu AM, Turcotte B. Largescale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae. Mol Pharmacol 2005;68:1365-75.
35. Game JC. The saccharomyces repair genes at the end of the century. Mutat Res 2000;451:277-93.
36. Longhese MP, Mantiero D, Clerici M. The cellular response to chromosome breakage. Mol Microbiol 2006;60:1099-108.
37. Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005;23:1951-61.
38. Araujo FD, Pierce AJ, Stark JM, Jasin M. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002;21:4176-80.
39. Thompson LH. Evidence that mammalian cells possess homologous recombinational repair pathways. Mutat Res 1996;363:77-88.
40. Legerski RJ, Richie C. Mechanisms of repair of interstrand cross-links in DNA. Cancer Treat Res 2002;112:109-28.
41. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand crosslinks in mammalian cells. Mol Cell Biol 2000;20:7980-90.
42. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
43. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
44. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005;25:7158-69.
45. Sung JS, Demple B. Analysis of base excision DNA repair of the oxidative lesion 2-deoxyribonolactone and the formation of DNA-protein cross-links. Methods Enzymol 2006;408:48-64.
46. Meyn RE, vanAnkeren SC, Jenkins WT. The induction of DNA-protein cross-links in hypoxic cells and their possible contribution to cell lethality. Radiat Res 1987;109:419-29.
47. Murray D, Vallee-Lucic L, Rosenberg E, Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res 2002;22:21-6.
48. Ganley B, Chowdhury G, Bhansali J, Daniels JS, Gates KS. Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide. Bioorg Med Chem 2001;9:2395-401.
49. Peters KB, Wang H, Brown JM, Iliakis G. Inhibition of DNA replication by tirapazamine. Cancer Res 2001;61:5425-31.
50. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-6.
51. Goldberg Z, Evans J, Birrell G, Brown JM. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin. Int J Radiat Oncol Biol Phys 2001;49:175-82.